In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...
Read More
In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read More
In a nutshell The study evaluated outcomes after stopping PEG–asparaginase (PEG-ANAse; Oncaspar) and substituting with Erwinia ASNase (Elspar) in children with B-cell acute lymphoblastic leukemia (B-ALL). The main finding was that completely stopping ASNase was associated with poorer outcomes in such patients. Some background...
Read More
In a nutshell This study examined how effective and safe a higher radiotherapy dose was for patients with non-Hodgkin lymphoma (NHL) undergoing stem cell transplantation (SCT). The authors found that patients who received a lower radiotherapy dose survived longer and had fewer side effects than the higher dose. Some background NHL is a cancer of...
Read MoreIn a nutshell The study evaluated the occurrence and risks of joint/muscle pain as side effects of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL). The authors found that 36% of patients developed joint/muscle pain and most were younger and females receiving ibrutinib as the first treatment. Some background Ibrutinib kills...
Read MoreIn a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing...
Read MoreIn a nutshell This study investigated preimplantation genetic testing for aneuploidy (PGT-A) for fertility preservation (FP). They found that PGT-A was useful in cancer patients attempting FP. Some background Assisted reproductive technology (ART) is used to treat infertility. It is also an important option for cancer patients. Cancer...
Read MoreIn a nutshell This study aimed to investigate if pretreatment with methylprednisolone would reduce infusion-related reactions associated with obinutuzumab use in patients with chronic lymphocytic leukemia. This study concluded that premedication with methylprednisolone reduces infusion-related reactions...
Read MoreIn a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...
Read MoreIn a nutshell This study aimed to investigate the effects of valproate (Depakene) and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia. This study concluded that the addition of ATRA to decitabine (Dacogen) chemotherapy led to a higher remission rate and survival...
Read MoreIn a nutshell This study aimed to investigate if fertility preservation in patients with invasive breast cancer would affect disease-free survival. This study concluded that fertility preservation appears unlikely to affect disease-free survival in these patients. Some background Fertility preservation (FP) is the process of saving or...
Read MoreIn a nutshell This study examined whether it is safe to switch from intravenous to subcutaneous rituximab (Rituxan) during first-line treatment of non-Hodgkin's lymphoma (NHL). The authors concluded that subcutaneous rituximab was safe and effective, and improved quality of life for patients. Some background Rituximab is a standard...
Read More
